Inhibikase Therapeutics (IKT) - Qarzning balans kapitallashuviga nisbati
Inhibikase Therapeutics (IKT) Parkinson kasalligini davolash uchun maxsus c-Abl kinaza inhibitorlarini ishlab chiqmoqda va narxlar grafigida aniq ko'rsatilganidek, o'z ishlanmalarini patentlar bilan himoya qilmoqda. Biznes modeli ishlab chiqarish va sinovlarni autsorsing qilishga asoslangan bo'lib, bu esa ulkan kapital xarajatlarini bartaraf etadi. Joriy ko'rsatkich 0.00 darajasida turibdi, moliyaviy barqarorlik saqlanmoqda, loyihaning muvaffaqiyati esa FDA tasdig'i va klinik sinovlarning samaradorligiga bog'liq.
&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_IKT_-_Inhibikase-Therapeutics_-_Debts-to-Book-Value "IKT Inhibikase Therapeutics Balans kapitallashuviga qarzlar (04.07.2022 - 30.10.2026) | 👁️GURU.Markets👁️")
Inhibikase Therapeutics Inc (IKT) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- bozor narxi va tahlilchilarning maqsadli narxlari:
- bozor kapitallashuvi ko'rsatkichlari:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Inhibikase Therapeutics|IKT - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning kapitalga nisbati Inhibikase|IKT - Kompaniyaning umumiy qarz majburiyatlari|Balans kapitallashuviga qarzlar Inhibikase Pharma|IKT - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzlari Inhibikase Therapeutics|Tezkor likvidlik inhibikase.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning har tomonlama tahlili:Inhibikase Therapeutics IKT
Ushbu ko'rsatkich kapital tuzilmasining aktivlarning balans qiymatiga nisbatan qarz mablag'lariga bog'liqligini o'lchaydi, bunda ko'rsatkichning pasayishi defoltga nisbatan chidamlilikning ortganidan dalolat beradi. Inhibikase Therapeutics (IKT) kompaniyasining balans kapitalida qarz majburiyatlari ulushi grafigini tahlil qilish orqali investor qimmatbaho klinik sinovlar va patent portfelining spekulyativ tabiati fonida kompaniyaning moliyaviy leverajini baholashi mumkin.
Inhibikase Therapeutics kimlar bilan raqobatlashadi
Qarzning balans kapitallashuviga nisbati Biogen Inc. BIIB|Qarzning sof aktivlarga nisbati NBIX|RGC - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar Axsome|ACAD: Balans kapitallashuviga qarzlar|XENE - Sof aktivlarga qarzlar|Qarzning balans kapitallashuviga nisbati Viking Therapeutics|Qarzning balans qiymatiga nisbati SUPN (supernus.com)|Balans kapitallashuviga qarzlar CPRX|DNLI (Denali) - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar HRMY (Harmony Pharma)|Sof aktivlarga qarzlar Biohaven Corp (BHVN)|Amylyx Pharmaceuticals - Balans kapitallashuviga qarzlar|TRVI: Qarzning balans kapitallashuviga nisbati|PRAX: Balans kapitallashuviga qarzlar|AVXL - Sof aktivlarga qarzlar|Qarzning balans kapitallashuviga nisbati CeriBell Corp|Balans kapitallashuviga qarzlar prothena.com|Balans kapitallashuviga qarzlar ALEC|Balans kapitallashuviga qarzlar annexonbio.com (ANNX)|Qarzning balans kapitallashuviga nisbati Omeros OMER|Sof aktivlarga qarzlar Neurogene Inc (NGNE)|AC Immune Corp - Balans kapitallashuviga qarzlar|Balans qiymatiga qarzlar Voyager Corp|NMRA (Neumora Therapeutics) - Qarzning balans qiymatiga nisbati|scilexholding.com - Qarzning sof aktivlarga nisbati|Qarzning balans qiymatiga nisbati TVGN|ACOG (Alpha Cognition Corp) - Qarzning balans kapitaliga nisbati|Balans kapitallashuviga qarzlar CGTX|SAVA (Cassava Pharma) - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Balans qiymatiga qarzlar|VTGN - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati OVID (Ovid Therapeutics Inc.)|ABOS: Balans kapitallashuviga qarzlar|CervoMed Corporation (CRVO) - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Alterity Therapeutics Ltd.|Clene Nanomedicine - Qarzlarning balans kapitallashuviga nisbati|Balans kapitallashuviga qarzlar PEPG|JUNS - Balans qiymatiga qarzlar|Relmada - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar Annovis Bio Corporation ANVS|GRCE: Qarzning balans qiymatiga nisbati|fireflyneuro.com - Qarzning balans kapitaliga nisbati|KLTO: Balans kapitallashuviga qarzlar|NRSN - Sof aktivlarga qarzlar|RVPH (Reviva Pharmaceuticals Holdings) - Balans kapitallashuviga qarzlar|Qarzning balans qiymatiga nisbati MetaVia, Inc. (MTVA)|Qarzning balans kapitallashuviga nisbati NeurAxis, Inc. (NRXS)|Sof aktivlarga qarzlar heliusmedical.com|Balans kapitallashuviga qarzlar PASG (Passage Bio)|Sof aktivlarga qarzlar Neuphoria Therapeutics, Inc. (NEUP)|NERV - Qarzning balans kapitallashuviga nisbati|ATHA - Balans kapitallashuviga qarzlar|ADXN (Addex Therapeutics) - Qarzning balans qiymatiga nisbati|ALZN: Qarzning balans kapitaliga nisbati|Qarzning balans kapitallashuviga nisbati Cyclerion Therapeutics Inc.|Qarzning balans qiymatiga nisbati PTIX (Protagenic)|Balans kapitallashuviga qarzlar KTTA|CRGT - Balans qiymatiga qarzlar|Avenue Therapeutics - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar brainstorm-cell.com BCLI|CARA - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati CHRO (Chromocell Therapeutics Corp)|eliemtx.com (ELYM) - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Balans kapitallashuviga qarzlar|marinuspharma.com (MRNS) - Sof aktivlarga qarzlar|Qarzning balans kapitallashuviga nisbati NKGen Biotech (NKGN)|NeuroBo Pharmaceuticals Inc - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar SAGE (Sage Therapeutics, Inc)|Qarzning sof aktivlarga nisbati SNPX|Trevena, Inc. - Balans kapitallashuviga qarzlar|Sof aktivlarga qarzlar Vigil Neuroscience VIGL|WENA: Balans kapitallashuviga qarzlar|CERE (Cerevel Therapeutics Inc) - Qarzning balans kapitallashuviga nisbati